Point of Care Diagnostics Market: Growth, Size, Share, and Trends

Report Code MD 2702
Published in Feb, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Point of Care Diagnostics Market by Product (Glucose, HIV, Hep C, HPV, Hematology, Pregnancy), Platform (Microfluidic, Dipstick, RT-PCR, INAAT), Sample (Blood, Urine), Purchase (OTC, Rx), End User (Pharmacy, Hospitals, Home Care) & Region - Global Forecast to 2028

Overview

The global point of care diagnostics market growth forecasted to transform from USD 49.7 billion in 2023 to USD 77.8 billion by 2028, driven by a CAGR of 9.4%. The growth of this market is attributed to the increasing prevalence of infectious diseases, cardiovascular diseases, and metabolic disorders such as diabetes. Additional factors include technological advancements in rapid tests, approvals of CLIA-waived PoC tests, the growing trend toward healthcare decentralization, and the increasing emphasis by manufacturers on developing affordable and user-friendly home-based rapid tests for various conditions. However, the stringent regulatory approval process for new PoC devices and increasing pricing pressure on PoC device manufacturers are expected to negatively impact the growth of the point-of-care diagnostics market.

Attractive Opportunities in the point of care diagnostics market

ASIA PACIFIC:

Market growth in Asia Pacific can be attributed to rising disposable incomes and increasing awareness about healthcare, large patient population, rising healthcare infrastructure, government initiatives to promote PoC adoption, increased collaboration and partnerships among key players in the region

The rising prevalence of infectious diseases, increase in number of rapid CLIA tests, supportive government policies, technological advancements are the key factors driving the point-of-care diagnostics market.

Rising investment and fundings on new PoC testing products, healthcare decentralization, healthcare decentralization, collaborations healthcare providers and players to intergrade PoC device, and growing adoption of home testing are contributing to the growth opportunities in PoC diagnostics market

The North American point-of-care diagnostics market is projected to reach USD 30.5 billion by 2028, growing at a CAGR of 9.2% during the forecast period.

Asia Pacific is the fastest-growing regional market for point-of-care diagnostic products, with China and India emerging as major growth hotspots.

Global point of care diagnostics market Dynamics

DRIVER: Increasing prevalence of infectious diseases globally

POC tests can primarily improve the management of infectious diseases, especially in emerging markets and resource limited settings. According to UNAIDS, approximately 39 million people were suffering from HIV-AIDS globally as of 2022, and an estimated 1.3 million individuals acquired HIV.In 2022, Tuberculosis ranked as the second leading cause of death globally among single infectious agents following COVID-19. Globally, the newly diagnosed tuberculosis cases reached 7.5 million in 2022 (Source: WHO Global Tuberculosis Report 2023). Point-of-care tests with high sensitivity and specificity enable the rapid diagnosis of infectious diseases, initiating prompt treatment further enhancing patient outcome. The global rise in prevalence of infectious diseases such as malaria, tuberculosis, HIV are likely to boost the demand for point-of-care diagnostics

RESTRAINT: Pricing pressure on PoC Manufacturers

Intense competition in the POC testing market can lead to pricing pressure, Moreover, decrease in reimbursement rates for POC tests from government payers, private insurers, or healthcare reimbursement programs are driving down profit margins for manufacturer significantly impacting the growth of point of care diagnostics market. Healthcare facilities, especially those in areas with limited resources or financial constraints, may have constrained budgets for investing in point-of-care testing equipment and materials, limiting the adoption of point of care testing.

OPPORTUNITY: High growth potential of emerging markets

Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players operating in the POC diagnostics market. This is primarily due to the high and growing prevalence of infectious and lifestyle diseases in these countries. To meet the increasing demand for POC diagnostics in emerging markets, manufacturers focus on acquiring or entering into agreements and partnerships with regional/domestic players for product distribution and manufacturing. Regulatory policies in the Asia Pacific region are flexible and have less stringent regulations than established markets in North America and Europe. The saturation of mature markets will further compel manufacturers and leading POC testing companies to shift their focus to emerging markets

CHALLENGE: Inadequate standardization with centralized lab methods

POC test results lack alignment with central lab methods due to many pre- and post-analytical errors. Pre-analytical errors for POC testing include unsuitable indications for the performance of the test, inappropriate sampling times and techniques, lack of information about patient conditions, and other factors such as fasting before functional tests or variations in posture/position during similar tests. On the other hand, post-analytical errors include inadequate technical validation, false assignment of results, and errors in data storage.POC testing is often conducted in emergencies to facilitate clinical decision-making. In several cases, these tests are conducted by nurses or clinical team members, not physicians. These issues can potentially lead to erroneous diagnoses and affect the quality of patient care. Considering such issues, patients & doctors can decide not to opt for POC testing. This is one of the critical challenges to the higher acceptance of POC testing.

Global Point of Care Diagnostics Market Ecosystem Analysis

The Glucose Monitoring Product segment to hold significant share of the global point of care diagnostics industry, by product type, in 2022 Based on the product, point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, COVID-19 testing products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, hematology testing products, cancer marker testing products, fecal occult testing products, urinalysis testing products, drug-of-abuse testing products, thyroid-stimulating hormone (TSH) testing products, cholesterol testing products, and other products. In 2022, the glucose monitoring testing products segment accounted for the second largest share of the market. The significant rise in the diabetes cases globally, widespread adoption of glucose monitoring kits, and greater awareness of the diabetes care are expected to propel the growth of the segment

By platform, the lateral flow assay segment held the largest share of point of care diagnostics industry

Based on platform, the point of care diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics. The lateral flow assays segment accounted for the largest share of the market in 2022. Lateral flow assay is more affordable compared to traditional laboratory testing methods, moreover the ease of conducting lateral flow assay makes this technology well suited for healthcare settings with limited resources, enabling rapid testing for various conditions.

By End User, home care settings and self testing of the point of care diagnostics industry to grow at a significant rate from 2023-2028

Based on end user, home care setting and self-testing segment is expected to grow at a significant rate owing to growing awareness about home care, increasing availability of user-friendly and advanced POC diagnostic products, including blood glucose, cholesterol, and pregnancy. Additionally, the COVID 19 pandemic has accelerated the adoption of home care self-testing products, particularly for diagnostic testing and monitoring of infectious diseases. Along with this the rising partnerships, and collaborations among various players to develop novel rapid testing products for home use are likely to contribute towards the rapid growth of the segment

NORTH AMERICA Region Holds the Largest Share of the Point of Care Diagnostics Market.

North America is the expected to be the largest regional market for point of care diagnostics during the forecast period. The presence of a well-established healthcare system, rapid adoption of advanced point of care testing products, increase in the availability of medical reimbursement, favourable government support for the novel product development, and higher user awareness about the presence of point of care testing products are anticipated to support the market growth in the region

Recent Developments of point of care diagnostics market industry

  • In May 2023, bioMérieux received the US FDA CLIA-waiver for the BIOFIRE SPOTFIRE Respiratory (R) Panel Mini,a second multiplex PCR-based test cleared for use on the BIOFIRE SPOTFIRE System In August 2023, BD received the US FDA approval for its BD Respiratory Viral Panel (RVP) for BD MAX System, a single molecular diagnostic combination test that identifies & distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in ~ 2 hours.
  • In December 2023, Thermo Fisher Scientific Inc. and Project HOPE, a leading global health and humanitarian organization, partnered to expand the accessibility of HIV testing services offered by Thermo Fisher among HIV Positive Youth in Sub-Saharan Africa.

Key Market Players

KEY PLAYERS IN THE point of care diagnostics market INCLUDE

Want to explore hidden markets that can drive new revenue in Point of Care Diagnostics Market?

Scope of the Report

Report Attribute Details
Market Revenue Size in 2023 USD 49.7 billion
Projected Revenue Size by 2028 USD 77.8 billion
Industry Growth Rate Poised to Grow at a CAGR of 9.4%
Market Driver Increasing prevalence of infectious diseases globally
Market Opportunity High growth potential of emerging markets

 

Key Questions Addressed by the Report

What is the projected growth rate and market value of the global point of care diagnostics market?
The global point-of-care diagnostics market is projected to grow from USD 49.7 billion in 2023 to USD 77.8 billion by 2028, demonstrating a robust CAGR of 9.4%.
What are the key drivers of the point of care diagnostics market?
Key drivers of the point of care diagnostics market include the growing incidence of infectious diseases, advancements in rapid diagnostic technologies, approvals of CLIA-waived PoC tests, and the increasing demand for decentralized healthcare solutions.
How is the increasing prevalence of infectious diseases affecting the market?
The rising prevalence of infectious diseases, including influenza, COVID-19, and sexually transmitted infections, is driving the demand for rapid point of care diagnostic tests, contributing significantly to market growth.
Which regions are expected to show significant growth in the point of care diagnostics market?
The Asia Pacific region is expected to register significant growth in the point of care diagnostics market, driven by increasing healthcare infrastructure, rising patient populations with conditions like diabetes and cardiovascular diseases, and growing healthcare expenditures.
What are the major product segments in the point of care diagnostics market?
Major product segments in the point of care diagnostics market include glucose monitoring products, infectious disease PoC testing products, pregnancy and fertility PoC tests, coagulation monitoring products, and various other PoC test kits for conditions like cardiac biomarkers and cancer markers.
What are the challenges faced by the point of care diagnostics market?
Challenges faced by the market include stringent regulatory approval processes for new devices, pricing pressure on manufacturers, and the need for continuous advancements in diagnostic accuracy and technology.
How are technological advancements shaping the point of care diagnostics market?
Technological advancements, such as the development of rapid, user-friendly PoC test kits, automation, and molecular diagnostics, are significantly improving diagnostic accuracy and efficiency, which is helping to drive the growth of the point of care diagnostics market.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Point of Care Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
25
RESEARCH METHODOLOGY
32
EXECUTIVE SUMMARY
43
PREMIUM INSIGHTS
47
MARKET OVERVIEW
51
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising incidence of infectious diseases
    - Increasing prevalence of target conditions
    - Favorable government initiatives for POC testing
    - Rising number of CLIA-waived POC tests
    RESTRAINTS
    - Pricing pressure on POC manufacturers
    - Stringent regulatory approval process for product commercialization
    OPPORTUNITIES
    - High growth potential of emerging markets
    - Decentralization of healthcare
    - Innovative product development
    CHALLENGES
    - Inadequate standardization with centralized lab methods
    - Limited awareness in emerging markets
    - Premium pricing of novel platforms
  • 5.3 TECHNOLOGY ANALYSIS
    POC TESTS WITH MULTIPLEXING CAPABILITIES
    STROKE/CARDIAC MARKERS
    THYROID TESTING
    DNA TESTING
    ENDOCRINE TESTING
    RESPIRATORY DIAGNOSTICS
  • 5.4 REGULATORY LANDSCAPE
    KEY REGULATORY GUIDELINES
    - US
    - Canada
    - Europe
    - Japan
    - China
    - India
    - Brazil
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
    PROMINENT COMPANIES
    SMALL & MEDIUM-SIZED ENTERPRISES
    END USERS
    PRICING ANALYSIS
    - Average selling price trend
  • 5.7 PORTER’S FIVE FORCES ANALYSIS
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 TRADE DATA
  • 5.9 REIMBURSEMENT SCENARIO
  • 5.10 PATENT ANALYSIS
    ECOSYSTEM/MARKET MAP
    KEY CONFERENCES & EVENTS
  • 5.11 CASE STUDY ANALYSIS
    DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I
  • 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14 BUYING CRITERIA
POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE
81
  • 6.1 INTRODUCTION
  • 6.2 OTC TESTING PRODUCTS
    GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET
  • 6.3 PRESCRIPTION-BASED TESTING PRODUCTS
    RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM
85
  • 7.1 INTRODUCTION
  • 7.2 LATERAL FLOW ASSAYS
    RISING ADOPTION OF TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET
  • 7.3 IMMUNOASSAYS
    UTILIZATION IN INFECTIOUS DISEASE TESTING TO SUPPORT MARKET GROWTH
  • 7.4 MICROFLUIDICS
    GROWING TREND OF MINIATURIZATION AND RISING TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET
  • 7.5 DIPSTICKS
    QUALITATIVE ANALYSIS OF MEDICAL CONDITIONS TO SUPPORT MARKET GROWTH
  • 7.6 MOLECULAR DIAGNOSTICS
    RT-PCR
    - Rising cases of COVID-19 to boost demand
    INAAT
    - Cost benefits of INAAT to propel segment growth
    OTHER TECHNOLOGIES
POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE
94
  • 8.1 INTRODUCTION
  • 8.2 BLOOD SAMPLES
    HIGH UTILIZATION IN DISEASE DETECTION TO DRIVE MARKET
  • 8.3 URINE SAMPLES
    INCREASING PREVALENCE OF KIDNEY DISORDERS AND WIDE RANGE OF DIAGNOSTIC TARGETS TO BOOST DEMAND
  • 8.4 NASAL & OROPHARYNGEAL SWABS
    RISING INCIDENCE OF RESPIRATORY INFECTIONS TO PROPEL MARKET
  • 8.5 OTHER SAMPLES
POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT
98
  • 9.1 INTRODUCTION
  • 9.2 GLUCOSE MONITORING PRODUCTS
    STRIPS
    - Ability to provide single-use measurement testing to drive market
    METERS
    - Ability to adjust therapeutic regimens daily to support market growth
    LANCETS & LANCING DEVICES
    - Provision of multiple depth penetration settings to boost demand
  • 9.3 COVID-19 TESTING PRODUCTS
    RISING UPTAKE OF RT-PCR RAPID TESTS TO BOOST DEMAND
  • 9.4 CARDIOMETABOLIC MONITORING PRODUCTS
    CARDIAC MARKER TESTING PRODUCTS
    - Rising government initiatives for CVD research to drive market
    BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
    - Technological advancements in monitoring products to support market growth
    HBA1C TESTING PRODUCTS
    - Favorable clinical outcomes with long-term monitoring to drive market
  • 9.5 INFECTIOUS DISEASE TESTING PRODUCTS
    HIV TESTING PRODUCTS
    - Rising prevalence of HIV to drive market
    RESPIRATORY INFECTION TESTING PRODUCTS
    - Rising incidence of respiratory infections to drive market
    HEPATITIS C TESTING PRODUCTS
    - Increasing prevalence of viral hepatitis to support market growth
    HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
    - High incidence of UTIs and surgical-site infections to boost demand
    INFLUENZA TESTING PRODUCTS
    - Ability to identify A & B viral nucleoprotein antigens to drive market
    TROPICAL DISEASE TESTING PRODUCTS
    - Rising incidence of malaria and dengue to support market growth
    SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
    - Syphilis testing products
    - Human papillomavirus (HPV) testing products
    - Chlamydia trachomatis testing products
    - Herpes simplex virus (HSV) testing products
    TUBERCULOSIS
    - Rising prevalence of TB in underserved areas to support market growth
    CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
    - Rising cases among hospitalized patients to boost demand
    OTHER INFECTIOUS DISEASE TESTING PRODUCTS
  • 9.6 COAGULATION MONITORING PRODUCTS
    PT/INR TESTING PRODUCTS
    - Ability to detect blood clots to support market growth
    ACT/APTT TESTING PRODUCTS
    - Rising cases of dialysis and ESRD to boost demand
  • 9.7 PREGNANCY & FERTILITY TESTING PRODUCTS
    PREGNANCY TESTING PRODUCTS
    - Growing preference for home care testing to drive market
    FERTILITY TESTING PRODUCTS
    - Growing focus on family planning to boost demand
  • 9.8 TUMOR/CANCER MARKER TESTING PRODUCTS
    INCREASING INCIDENCE OF CANCER AND RISING UPTAKE OF IMMUNOASSAYS TO PROPEL MARKET
  • 9.9 URINALYSIS TESTING PRODUCTS
    HIGH INCIDENCE OF RECURRENT UTIS TO DRIVE MARKET
  • 9.10 CHOLESTEROL TESTING PRODUCTS
    RISING OBESITY LEVELS AND INCIDENCE OF CVD TO BOOST DEMAND
  • 9.11 HEMATOLOGY TESTING PRODUCTS
    PREFERENCE FOR LABORATORY-BASED TESTS TO RESTRAIN MARKET
  • 9.12 DRUGS-OF-ABUSE TESTING PRODUCTS
    RISING CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET
  • 9.13 THYROID-STIMULATING HORMONE (TSH) TESTING PRODUCTS
    RISING CASES OF THYROID TO BOOST DEMAND
  • 9.14 FECAL OCCULT TESTING PRODUCTS
    INCREASING AWARENESS ON EARLY DISEASE DETECTION TO SUPPORT MARKET GROWTH
  • 9.15 OTHER PRODUCTS
POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER
131
  • 10.1 INTRODUCTION
  • 10.2 CLINICAL LABORATORIES
    IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST DEMAND
  • 10.3 AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES
    RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE TO DRIVE MARKET
  • 10.4 PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS
    ABILITY TO SUPPORT CHRONIC DISEASE MANAGEMENT TO BOOST DEMAND
  • 10.5 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
    RAPID RESULTS AND END USERS OF POC DIAGNOSTICS
  • 10.6 HOME CARE SETTINGS AND SELF-TESTING
    GROWING INCLINATION TOWARDS REMOTE-BASED CARE TO DRIVE MARKET
  • 10.7 OTHER END USERS
POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION
138
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    NORTH AMERICA: RECESSION IMPACT
    US
    - Favorable government support and medical reimbursements to boost demand
    CANADA
    - Rising incidence of diabetes and cancer to support market growth
  • 11.3 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Rising demand for innovative technologies to propel market
    FRANCE
    - Growing public-private collaborations for product development to drive market
    UK
    - Growing number of accredited diagnostic & hospital laboratories to propel market
    ITALY
    - Increasing adoption of infectious disease diagnostics to drive market
    SPAIN
    - Rising incidence of chronic diseases to support market growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    JAPAN
    - Availability of advanced rapid flu tests to drive market
    CHINA
    - Rising incidence of infectious diseases to drive market
    INDIA
    - High burden of chronic diseases to propel market
    AUSTRALIA
    - Increasing research investments for next-gen POC devices to fuel market
    SOUTH KOREA
    - Growing awareness about advanced POC devices to boost demand
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    LATIN AMERICA: RECESSION IMPACT
    BRAZIL
    - Rising prevalence of diabetes to support market growth
    MEXICO
    - Rising incidence of cancer to drive market
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    MIDDLE EAST & AFRICA: RECESSION IMPACT
    - GCC Countries
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
199
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.3 REVENUE SHARE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT
    - Product & regional footprint
  • 12.6 START-UP/SME EVALUATION MATRIX
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING
  • 12.7 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    OTHER DEVELOPMENTS
COMPANY PROFILES
214
  • 13.1 KEY PLAYERS
    ABBOTT LABORATORIES
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SIEMENS HEALTHINEERS
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    QUIDELORTHO CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    DANAHER CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    BECTON, DICKINSON AND COMPANY
    - Business overview
    - Products offered
    - Recent developments
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products offered
    - Recent developments
    CHEMBIO DIAGNOSTICS, INC.
    - Business overview
    - Products offered
    - Recent developments
    EKF DIAGNOSTICS HOLDINGS PLC
    - Business overview
    - Products offered
    - Recent developments
    TRINITY BIOTECH PLC
    - Business overview
    - Products offered
    - Recent developments
    WERFEN, S.A.
    - Business overview
    - Products offered
    - Recent developments
    NOVA BIOMEDICAL
    - Business overview
    - Products offered
    - Recent developments
    PTS DIAGNOSTICS
    - Business overview
    - Products offered
    - Recent developments
    SEKISUI DIAGNOSTICS
    - Business overview
    - Products offered
    - Recent developments
    EUROLYSER DIAGNOSTICA GMBH
    - Business overview
    - Products offered
    RESPONSE BIOMEDICAL
    - Business overview
    - Products offered
    - Recent developments
    ALFA SCIENTIFIC DESIGNS, INC.
    - Business overview
    - Products offered
    BODITECH MED INC.
    - Business overview
    - Products offered
    - Recent developments
    BTNX INC.
    - Business overview
    - Products offered
  • 13.2 OTHER PLAYERS
    LIFESCAN IP HOLDINGS, LLC
    ASCENSIA DIABETES CARE HOLDINGS AG
    FLUXERGY
    PRECISION BIOSENSOR, INC.
    ACON LABORATORIES, INC.
    A. MENARINI DIAGNOSTICS S.R.L.
    ORASURE TECHNOLOGIES, INC.
    MANKIND PHARMA
    GRIFOLS, S.A.
    DIASORIN S.P.A.
APPENDIX
305
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
  • TABLE 2 RECENT WAIVERS FOR PRODUCTS
  • TABLE 3 REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 4 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 5 AVERAGE SELLING PRICE OF LEADING PRODUCTS, BY KEY PLAYER (USD)
  • TABLE 6 AVERAGE PRICE OF GLUCOSE MONITORING & CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022 (USD)
  • TABLE 7 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022 (USD)
  • TABLE 8 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2022 (USD)
  • TABLE 9 POINT-OF-CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 10 IMPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018–2021 (USD MILLION)
  • TABLE 11 EXPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018–2021 (USD MILLION)
  • TABLE 12 KEY MEDICARE CLINICAL LAB FEE SCHEDULE (CLFS) CODES FOR COVID-19 TESTING
  • TABLE 13 MEDICARE HCPCS CODES FOR HIV TESTING
  • TABLE 14 POINT-OF-CARE DIAGNOSTICS MARKET: LIST OF KEY CONFERENCES & EVENTS (2023−2024)
  • TABLE 15 CASE 1: DIAGNOSING LOWER LEVELS OF TROPONIN IN CARDIAC PATIENTS
  • TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR POINT-OF-CARE TESTING KITS AND INSTRUMENTS (%)
  • TABLE 17 KEY BUYING CRITERIA FOR POC PRODUCTS
  • TABLE 18 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
  • TABLE 19 OTC TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 20 PRESCRIPTION-BASED TESTING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 21 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
  • TABLE 22 POINT-OF-CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 23 POINT-OF-CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 24 POINT-OF-CARE DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2021–2028 (USD MILLION)
  • TABLE 27 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 28 POINT-OF-CARE DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 29 POINT-OF-CARE DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
  • TABLE 32 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 33 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 39 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 40 GLUCOSE MONITORING METERS MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 41 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 51 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 52 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 58 POINT-OF-CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 62 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 63 POINT-OF-CARE DIAGNOSTICS MARKET FOR CDI, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 64 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 65 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 66 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 67 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 68 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 69 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 70 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 71 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 72 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 73 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 74 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 75 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 76 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2021–2028(USD MILLION)
  • TABLE 77 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 78 POINT-OF-CARE DIAGNOSTICS MARKET FOR TSH TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 79 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 80 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 81 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 82 POINT-OF-CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 83 POINT-OF-CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 84 POINT-OF-CARE DIAGNOSTICS MARKET FOR PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 85 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 86 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 87 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 88 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
  • TABLE 89 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 90 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 91 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 92 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 93 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 94 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 95 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 96 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
  • TABLE 97 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
  • TABLE 98 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 99 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
  • TABLE 100 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 101 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 102 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 103 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 104 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 105 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 106 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 107 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 108 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 109 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
  • TABLE 110 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
  • TABLE 111 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 112 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
  • TABLE 113 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 114 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 115 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 116 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 117 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 118 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 129 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
  • TABLE 130 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 131 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 132 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 133 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION
  • TABLE 134 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 135 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 136 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 137 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 138 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 139 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 140 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 141 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 142 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 143 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
  • TABLE 144 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
  • TABLE 145 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 146 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
  • TABLE 147 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 148 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 149 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 150 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
  • TABLE 151 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 152 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 153 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 154 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 155 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 156 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
  • TABLE 157 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
  • TABLE 158 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
  • TABLE 159 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
  • TABLE 160 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
  • TABLE 161 GCC COUNTRIES: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 162 REST OF AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 163 REST OF MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
  • TABLE 164 OVERALL FOOTPRINT
  • TABLE 165 PRODUCT FOOTPRINT
  • TABLE 166 REGIONAL FOOTPRINT
  • TABLE 167 POINT-OF-CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 168 POINT-OF-CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–NOVEMBER 2023)
  • TABLE 169 POINT-OF-CARE DIAGNOSTICS MARKET: DEALS (JANUARY 2020–NOVEMBER 2023)
  • TABLE 170 POINT-OF-CARE DIAGNOSTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2020–NOVEMBER 2023)
  • TABLE 171 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 172 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 173 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
  • TABLE 174 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 175 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 176 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 177 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 178 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
  • TABLE 179 BIOMÉRIEUX : COMPANY OVERVIEW
  • TABLE 180 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • TABLE 181 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
  • TABLE 182 TRINITY BIOTECH PLC: COMPANY OVERVIEW
  • TABLE 183 WERFEN: COMPANY OVERVIEW
  • TABLE 184 NOVA BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 185 PTS DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 186 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 187 EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW
  • TABLE 188 RESPONSE BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 189 ALFA SCIENTIFIC DESIGNS, INC: COMPANY OVERVIEW
  • TABLE 190 BODITECH MED INC.: COMPANY OVERVIEW
  • TABLE 191 BTNX INC.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 3 BREAKDOWN OF PRIMARIES
  • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 5 POINT-OF-CARE DIAGNOSTICS MARKET: MARKET SIZE ESTIMATION METHODOLOGY
  • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • FIGURE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
  • FIGURE 8 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2023 VS. 2028 (USD MILLION)
  • FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2023 VS. 2028 (USD MILLION)
  • FIGURE 10 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
  • FIGURE 11 GEOGRAPHIC SNAPSHOT OF POINT-OF-CARE DIAGNOSTICS MARKET
  • FIGURE 12 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 13 INFECTIOUS DISEASE TESTING PRODUCTS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 14 OTC TESTING PRODUCTS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • FIGURE 15 LATERAL FLOW ASSAYS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 17 POINT-OF-CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 18 REGIONAL INCIDENCE OF HIV (2022)
  • FIGURE 19 US: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 20 CANADA: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 21 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 22 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 23 INDIA: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 24 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
  • FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION & DISTRIBUTION STAGES
  • FIGURE 26 SUPPLY CHAIN ANALYSIS
  • FIGURE 27 AVERAGE SELLING PRICE OF TOP 2 LEADING PRODUCTS, BY KEY PLAYER
  • FIGURE 28 TOP 10 PATENT OWNERS FOR POINT-OF-CARE DIAGNOSTICS (JANUARY 2012–DECEMBER 2023)
  • FIGURE 29 ANALYSIS OF PARENT MARKET: IN VITRO DIAGNOSTICS MARKET
  • FIGURE 30 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
  • FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE TESTING KITS & INSTRUMENTS
  • FIGURE 32 KEY BUYING CRITERIA FOR POINT-OF-CARE TESTING KITS & INSTRUMENTS
  • FIGURE 33 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 34 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 35 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN POINT-OF-CARE DIAGNOSTICS MARKET
  • FIGURE 36 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN POINT-OF-CARE DIAGNOSTICS MARKET (2022)
  • FIGURE 37 POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
  • FIGURE 38 COMPANY EVALUATION MATRIX
  • FIGURE 39 START-UP/SME EVALUATION MATRIX
  • FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
  • FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
  • FIGURE 42 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023)
  • FIGURE 43 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
  • FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 47 BIOMÉRIEUX : COMPANY SNAPSHOT (2022)
  • FIGURE 48 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 49 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2022)
  • FIGURE 50 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2022)
  • FIGURE 51 WERFEN, S.A.: COMPANY SNAPSHOT (2022)

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the point of care diagnostics market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the point of care diagnostics market. The primary sources from the demand side include hospitals, clinical laboratories, pharmacies, ecommerce platforms, physician’s office, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2022, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Point-of-Care Diagnostics Market Size, and Share

*C-level primaries include CEOs, CFOs, COOs, and VPs.

**Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue; as of 2021, Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology:

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global point of care diagnostics market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players (who contribute at least 85–90% of the market share at the global level). Also, the global point of care diagnostics market was split into various segments and sub-segments based on:

  • list of major players operating in the point-of-care market at the regional and/or country level
  • Product mapping of various manufacturers for point-of-care diagnostics products at the regional and/or country level
  • Mapping of annual revenue generated by listed major players from point-of-care diagnostics segments (or the nearest reported business unit/product category)
  • Revenue mapping of major players to cover at least 65–75% of the global market share as of 2022
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global point-of-care  diagnostics market

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Point-of-Care Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation:

After deriving the overall Point of care diagnostics  market value data from the market size estimation process, the total market value data was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all the segments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various qualitative and quantitative variables as well as by analyzing regional trends for both the demand- and supply-side macro indicators.

Market Definition:

Point of care testing includes  conducting diagnostic tests near the patient, offering  immediate results enabling helathacare providers to expedite the clinical decisions. Point of care devices are best suited for  various healthcare settings, including clinical laboratories , hospitals, physician offices, ambulances, and at  homes, emergency rooms

Key Market Stakeholders:

  • Point-of-care Diagnostic Product Manufacturers
  • Distributors, Channel Partners, and Third-party Suppliers
  • Clinical Laboratories, Reference Laboratories, and Contract Testing Laboratories
  • Hospitals, Diagnostic Clinics, and Sports/Military Facilities
  • Contract Manufacturing Organizations (CMOs)
  • Contract Research Organizations (CROs)
  • R&D Companies
  • Business Research and Consulting Service Providers
  • Medical Research Laboratories
  • Academic Medical Centers, Universities, and Hospitals

Report Objectives:

  • To define, describe, and forecast the point-of-care diagnostics  market by Product, Platform, Mode of Purchase, Sample, End User, and Region
  • To provide detailed information about major factors influencing market growth (key drivers, restraints, opportunities, and industry-specific challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and their contributions to the overall point-of-care and rapid diagnostics   market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the market value of various segments and sub-segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players active in the point of care diagnostics market and comprehensively analyze their global revenue shares and core competencies
  • To track and analyze competitive market-specific developments such as product approvals & commercialization, agreements, partnerships, collaborations, acquisitions, and expansions in the point-of-care diagnostics   market

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global point of care diagnostics  market report:

Product Analysis:

  • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

Company Information:

  • Detailed analysis and profiling of additional market players (up to 15)

Geographic Analysis:

  • Further breakdown of the Rest of Europe's point of care diagnostics  market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among other
  • Further breakdown of the Rest of Asia Pacific point of care diagnostics  market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries.

Previous Versions of this Report

Point of Care/ Rapid Diagnostics Market by Product (Glucose, HIV, Hepatitis C, Pregnancy), Platform (Microfluidics, Dipstick, Immunoassay), Purchase(OTC, Prescription), Sample(Blood, Urine), User (Pharmacy, Hospital, Homecare) - Global Forecast to 2027

Report Code MD 2702
Published in Dec, 2022, By MarketsandMarkets™

Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease(HIV, Hepatitis C), Pregnancy Test), Platform (Microfluidics, Dipsticks), Mode of Purchase (OTC, Prescription), End User (Pharmacy, Hospital, Home) - Global Forecast to 2027

Report Code MD 2702
Published in Mar, 2022, By MarketsandMarkets™

Point of Care/Rapid Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza), Coagulation), Platform (Microfluidics, Immunoassay), Mode of Purchase (Prescription, OTC), Enduser (Hospital, e-comm, Home Care) - Global Forecast to 2025

Report Code MD 2702
Published in Feb, 2021, By MarketsandMarkets™

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza, Respiratory), Coagulation), Platform (Microfluidics, Immunoassays), Mode (Prescription & OTC), End-User (Hospitals, Home Care) - Global Forecast to 2024

Report Code MD 2702
Published in Nov, 2019, By MarketsandMarkets™

Point-of-Care/Rapid Diagnostics Market by Testing (Glucose, Lipids, HbA1c, HCV, HIV, Influenza, Urinalysis, Hematology, Cancer, Pregnancy, PT/INR), Platform (Lateral Flow, Immunoassay), Mode (Prescription, OTC), End-User - Global Forecast to 2022

Report Code MD 2702
Published in Feb, 2018, By MarketsandMarkets™

Point-of-Care Diagnostics Market (Products-Glucose, Cardiometabolic Monitoring, & Infectious Disease Testing Kits, Cardiac & Tumor Markers), (End Users-Home, Hospitals, Ambulatory Care), (Over-the- Counter & Prescription Based) - Global Forecast to 2021

Report Code MD 2702
Published in Jul, 2016, By MarketsandMarkets™

Point-Of-Care Diagnostics / Testing Market by Products (Glucose Monitoring & Infectious Diseases Testing Kits, Cardiac & Tumor Markers), by End Users (Self & Professional Monitoring), Over the Counter & Prescription Based - Global Forecast to 2018

Report Code MD 2702
Published in Sep, 2014, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Point of Care Diagnostics Market

DMCA.com Protection Status